Neurogene to Participate in Stifel 2026 Virtual CNS Forum

Neurogene Inc. (Nasdaq: NGNE), a prominent clinical-stage biotechnology company focused on developing innovative genetic medicines for rare neurological diseases, has announced its participation in the Stifel 2026 Virtual CNS Forum. The event is scheduled for Wednesday, March 18, at 9:00 a.m. ET, where Company management will engage in a fireside chat to discuss Neurogene's advancements and strategic initiatives.

The fireside chat will be accessible via a live webcast from the Investor Relations section of Neurogene's website, providing investors and stakeholders an opportunity to gain insights into the company's ongoing projects. A replay of the discussion will also be made available for a limited time for those who are unable to attend the live event.

Neurogene is dedicated to transforming the lives of patients and their families impacted by severe neurological conditions through a biology-first approach in developing genetic therapies. Notably, the company is progressing its lead gene therapy program, NGN-401, which aims to be a one-time treatment for Rett syndrome—a devastating disorder primarily affecting females and characterized by a range of neurological impairments.

The company's cutting-edge research leverages its proprietary EXACT™ transgene regulation technology, which enables the design of tailored genetic medicines while optimizing delivery mechanisms. This positions Neurogene as a leader in the pursuit of effective therapies for rare genetic diseases.

For more information about Neurogene, its mission, and upcoming events, visit their website at neurogene.com or connect with them on LinkedIn. Contact details for company representatives are also provided for investor inquiries.

Neurogene Inc. (Nasdaq: NGNE) is positioned at the cutting edge of developing genetic medicines for rare neurological diseases, a sector that holds substantial promise as advancements in biotechnology evolve. With the upcoming participation in the Stifel 2026 Virtual CNS Forum on March 18, 2026, at 9:00 a.m. ET, Neurogene will provide insights into its strategic direction, technology platforms, and ongoing clinical programs. This public engagement represents an opportunity for investors to gain valuable perspective directly from management.

Neurogene's lead program, NGN-401, aims to deliver a one-time treatment for Rett syndrome—a condition that impacts numerous families worldwide. The company's proprietary EXACT™ technology enhances the delivery and efficacy of its therapies, positioning it as a potential leader in the growing field of gene therapy targeted at neurological disorders. Investors should note that the efficacy of NGN-401 and upcoming pipeline developments will be critical indicators of the company's market trajectory.

The growing interest in rare disease therapies offers significant market opportunities, and Neurogene’s focused approach sets it apart from competitors. The success of the fireside chat will hinge on how convincingly the management can communicate both the progress of its clinical trials and its vision for expanding its therapeutic pipeline.

As Neurogene gears up for this pivotal forum, investors are advised to closely monitor not only the insights shared during the event but also subsequent market reactions. Maintaining awareness of clinical trial results and partnership developments will be essential for assessing Neurogene's long-term value. With ongoing advancements in gene therapy, Neurogene warrants consideration as a potential investment in the biotechnology space, driven by its commitment to transformative patient solutions.